Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct;85(14):1307-1314.
doi: 10.1002/pros.70017. Epub 2025 Jul 27.

Prognostic Impact of Initial Prostate-Specific Antigen in Metastatic Hormone-Sensitive Prostate Cancer Patients With Extensive Bone Metastases Under Androgen Receptor Signaling Inhibitor

Saizo Fujimoto  1 , Tsuyoshi Morita  2 , Yutaka Yamamoto  3 , Masanobu Saruta  4 , Atsuhiko Yoshizawa  4 , Kiyoshi Takahara  4 , Takuya Tsujino  5 , Ryoichi Maenosono  5 , Yuki Yoshikawa  5 , Wataru Fukuokaya  6 , Takafumi Yanagisawa  6 , Takahiro Kimura  6 , Takeshi Hashimoto  7 , Yosuke Hirasawa  7 , Yoshio Ohno  7 , Kazutoshi Fujita  1
Affiliations

Prognostic Impact of Initial Prostate-Specific Antigen in Metastatic Hormone-Sensitive Prostate Cancer Patients With Extensive Bone Metastases Under Androgen Receptor Signaling Inhibitor

Saizo Fujimoto et al. Prostate. 2025 Oct.

Abstract

Objectives: We evaluated the association between initial prostate-specific antigen (iPSA) levels and prognosis in patients with high-risk metastatic hormone-sensitive prostate cancer (mHSPC) and extensive bone metastases treated with androgen receptor signaling inhibitors (ARSI).

Subjects and methods: This retrospective study included 276 de novo high-risk mHSPC patients with extensive bone metastases (extent of disease [EOD] score ≥ 2) who received ARSI as first-line therapy. The data were collected from institutions participating in the ULTRA Japan Study group. Patient data were collected from institutions affiliated with the ULTRAJ group. Patients were stratified into quartiles based on iPSA levels, and a cutoff value of 200 ng/mL was used for subgroup analysis. Overall survival (OS) and progression-free survival (PFS) were analyzed using Kaplan-Meier curves and Cox proportional hazards regression models. A restricted cubic spline analysis was conducted to evaluate the nonlinear association between iPSA levels and OS.

Results: Kaplan-Meier analysis demonstrated significant associations between iPSA quartiles and OS (p = 0.030), with the lowest survival observed in the lowest iPSA group (Q1: < 200 ng/mL). A spline-based analysis suggested an inverted J-shaped association between iPSA and OS, with the lowest hazard ratio observed at 1664 ng/mL. Patients with iPSA < 200 ng/mL exhibited significantly shorter OS than those with higher levels (p = 0.015), while no significant difference in PFS was observed (p = 0.869).

Conclusions: Initial PSA levels were associated with prognosis in high-risk mHSPC with extensive bone metastases. Although patients with relatively low iPSA had significantly shorter OS, those exhibited no significant difference in PFS, suggesting that patients with low iPSA could benefit from ARSI as the 1st line treatment.

Keywords: ULTRA Japan study; androgen receptor signaling inhibitor (ARSI); bone metastases; high‐risk metastatic prostate cancer; initial prostate‐specific antigen (initial PSA); metastatic hormone‐sensitive prostate cancer (mHSPC); prostate cancer; prostate‐specific antigen (PSA).

PubMed Disclaimer

References

    1. Y. Yamamoto, S. Fujimoto, M. Hashimoto, et al., “Real‐World Outcomes in Patients With Metastatic Castration‐Resistant Prostate Cancer Beyond Progression After Upfront Androgen Receptor Signaling Inhibitor,” International Journal of Clinical Oncology 29 (December 2024): 1946–1958.
    1. T. Uchimoto, K. Iwatsuki, K. Komura, et al., “Predicting Time to Castration Resistance With Androgen‐Receptor Signaling Inhibitors in Hormone‐Sensitive Prostate Cancer: Data From ULTRA‐Japan Consortium,” International Journal of Clinical Oncology 30 (October 2025): 123–133.
    1. T. Ueda, K. Hayakawa, G. Horiguchi, et al., “Screening for Predictive Factors of Efficacy of Second‐Generation Androgen Receptor Axis‐Targeted Agents in Patients With High‐Risk Metastatic Hormone‐Sensitive Prostate Cancer,” Prostate 85 (June 2025): 524–530.
    1. H. Sato, S. Narita, N. Tsuchiya, et al., “Impact of Early Changes in Serum Biomarkers Following Androgen Deprivation Therapy on Clinical Outcomes in Metastatic Hormone‐Sensitive Prostate Cancer,” BMC Urology 18, no. 1 (May 2018): 32.
    1. Y. Miyazawa, Y. Sekine, S. Arai, et al., “Prognostic Factors in Hormone‐Sensitive Prostate Cancer Patients Treated With Combined Androgen Blockade: A Consecutive 15‐Year Study at a Single Japanese Institute,” In Vivo 35, no. 1 (January 2021): 373–384.

MeSH terms